
Mental health struggles drive rise in school refusal among children, teens
IPOH: Rising cases of school refusal among children and adolescents in Malaysia are being driven by mental health struggles such as anxiety, bullying, family conflict and depression.
Consultant Child and Adolescent Psychiatrist at Hospital Permai Johor Bahru, Dr Nor Rahidah Abd Rahim, said the issue is often misunderstood, with many assuming that students simply 'do not want to go to school', when in fact the problem is rooted in deeper psychological issues that require clinical attention.
'Children don't refuse school without a reason. When we investigate, we often find underlying issues such as social anxiety, panic attacks, learning difficulties or even trauma,' she said during the Malaysian Child and Adolescent Mental Health and Psychiatry Conference (M-CHAMP) 2025, held here yesterday.
Dr Nor Rahidah said common triggers include separation anxiety in younger children, peer-related stress such as bullying, and academic pressure — all of which have become more evident since the COVID-19 pandemic.
'Post-pandemic, many students are struggling to re-adapt to school routines. Some feel overwhelmed by social situations they haven't encountered in two years,' she said, adding that prolonged online learning has also led to increased screen dependency and avoidance behaviours.
Dr Nor Rahidah stressed that school refusal is often mislabelled as truancy or misconduct, leading to delayed intervention and a worsening of the child's condition.
'Parents and teachers may think the child is lazy or disobedient. But when a child cries, complains of headaches, or begs not to go to school, it's usually a cry for help,' she said.
She called for stronger collaboration between schools, families and healthcare providers, and stressed the need for early detection and support.
'Teachers should be trained to recognise red flags. Schools must have clear referral pathways to mental health professionals,' she said.
She also warned that children who remain out of school for prolonged periods face serious risks, including academic decline, social isolation and worsening mental health symptoms — in some cases, requiring hospitalisation.
Dr Nor Rahidah said Hospital Permai, one of the few centres in Malaysia offering specialised child and adolescent psychiatry services, continues to see a rising number of referrals for school refusal — highlighting the urgent need for systemic support.
'School refusal is a silent epidemic. We need to act now with empathy, awareness, and coordinated care,' she said during her presentation titled Unpacking School Refusal: Understanding Its Roots and Psychological Underpinnings, under the main topic Fear to Flourish: School Refusal.
The three-day M-CHAMP 2025 conference, themed Mind in Bloom: Enhancing Child and Adolescent Wellbeing, ends today. It is being held at Casuarina Meru and brings together experts from across the country to share best practices and strategies for early intervention and community-based support.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Borneo Post
10 hours ago
- Borneo Post
Lingering shadow: Why Covid-19's return demands vigilance, not panic
Just when we thought the coast was clear, the familiar shadow of Covid-19 has returned. Just when we thought the coast was clear, the familiar shadow of Covid-19 has returned, uninvited, to our headlines and our communities. For months, we've enjoyed a semblance of normalcy – masks tucked away, social calendars full, and the virus relegated to a footnote. But recent reports from Thailand, Singapore, Malaysia, Hong Kong, and the US, all echoing the World Health Organization's (WHO) warnings, deliver an urgent, undeniable message: the pandemic's final act hasn't been written yet. This new surge, born from a cocktail of public fatigue, fading immunity, and viral evolution, demands a rapid recalibration of our approach. Not panic, but a sharp, intelligent focus on risk-based vigilance. The numbers are speaking volumes. Thailand's astonishing nearly 66,000 new cases in six days; Singapore's over 14,000 in a similar period; and Malaysia's consistent weekly average of 600, leading to over 11,000 cases in early 2025 – these are not minor fluctuations. The WHO's global confirmation of an 11% test positivity rate, a level not seen since mid-2024, signals a widespread upward trend, particularly across Southeast Asia and the Western Pacific. This resurgence is happening because people have become lax. Our reduced masking increased social mixing, and critically, the natural waning of both vaccine and infection-acquired immunity has created the perfect storm for transmission. The primary driver of this current surge is the NB.1.8.1 variant, now officially a WHO Variant Under Monitoring. Its defining characteristic is high transmissibility, allowing it to outcompete previous variants quickly, and now represents over 10% of global sequences. However, and this is a crucial point to understand amidst the alarm, NB.1.8.1 does not appear more virulent. Medical experts confirm there's no clear evidence it leads to higher hospitalization or death rates than its predecessors. Moreover, our existing vaccines are still holding strong, especially in preventing severe disease. Grasping this distinction – easily transmissible but not more severe – is key to a calm, effective response. So, what's the urgent takeaway for you? It's about shifting from a generalized 'over' mindset to informed, risk-based action. While the general, vaccinated population may experience symptoms akin to a bad cold, vulnerable groups face significantly higher risks of severe complications. If you or someone you care for falls into categories like the elderly, young children, pregnant individuals, or those with underlying health conditions (diabetes, heart disease, etc.), immediate heightened precautions are non-negotiable. For these vulnerable individuals, the action plan is simple and crucial: · Mask Up: In crowded indoor areas, or if you feel unwell. · Monitor and Test: Be acutely aware of symptoms. With flu, respiratory syncytial virus (RSV), and adenovirus also circulating, prompt Covid-19 antigen testing is vital for proper diagnosis and management. · Consult Your Doctor: Seek early medical advice. High-risk individuals might need additional evaluations. Crucially, if you have chronic conditions, maintain strict adherence to your medication. · Stay Vaccinated: Ensure your boosters are current. The vaccines remain effective against current strains.


The Star
11 hours ago
- The Star
New Zealand sees sharp rise in Covid-19, influenza
FILE PHOTO: People wearing masks walk pass Beehive, the Parliament building of New Zealand, in Wellington, New Zealand, May 10, 2022. - Xinhua WELLINGTON: New Zealand is experiencing a significant surge in Covid-19 and other respiratory infections, with recent data showing a sharp jump in hospitalisations and outbreaks across the country, Xinhua reported. Healthline, the national medical advice service, reported an uptick in calls related to influenza-like illnesses, although the volume remains lower than the same period last year, Radio New Zealand (RNZ) reported on Friday (June 6). The country is facing its coldest winter temperatures of the year, with some regions recently recording temperatures below zero and fresh snowfall covering parts of the South Island. Hospital admissions for severe respiratory infections in Auckland, the country's most densely populated region, rose by over 50 per cent in the week ending June 1, although overall levels remain similar to those seen last year. Nationwide wastewater testing also points to a growing increase in Covid-19 cases, according to the Institute of Environmental Science and Research. Health New Zealand has responded by increasing staffing, optimising hospital bed use, and intensifying vaccination campaigns, RNZ reported. Over one million people have received flu shots this year, but only about 250,000 are up to date with Covid-19 boosters, government statistics show. National Chief Medical Officer Prof. Helen Stokes-Lampard acknowledged the challenges in boosting vaccination rates, citing issues with vaccine confidence and healthcare access, according to the RNZ report. - Bernama/Xinhua


Malaysian Reserve
a day ago
- Malaysian Reserve
GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. MISSISSAUGA, ON, June 6, 2025 /CNW/ – GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country. Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap. Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies. 'As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges,' said Michelle Horn, Country Medical Director, GSK Canada. 'Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred.' Transforming Immunization Through Pharmacy Innovation The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include: Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations Leveraging digital health tools and technology to support clinical decision-making and personalized outreach Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services Implementing science methodologies to ensure successful and scalable solutions across regions and populations This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies. 'As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries,' said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. 'PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally.' Impact Beyond the Lab In addition to funding innovative research, GSK's investment will also: Provide funding to support new interdisciplinary projects with direct policy and practice implications Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention Establish a network of community pharmacies engaged in research, data collection and pilot projects Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public Strategic Alignment with Public Health and Policy This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development. 'Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare,' added Michelle Horn, Country Medical Director, GSK Canada. 'We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health.' Why Waterloo and Why Now? The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application. PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation. About the University of Waterloo School of PharmacyThe School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes. About GSK GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the 'Risk Factors' section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.